-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
-
Summary
-
PharmaCyte Biotech, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q1 2011 to Q1 2024.
- PharmaCyte Biotech, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending April 30, 2024 was $14.4M, a 8.23% decline year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)